Great learning experience from the most experienced organizations in the immunotherapy field. If networking and learning are your objectives, this is the place for you.

Josh Ludwig, Wilson Wolf

Definitely the best meeting we have attending in the last year where we could find potential pharma/biotech clients.

John R. Jaskowiak, Angiocrine Bioscience, Inc.

Phacilitate Washington 2014 at a glance:

- 500+ Attendees
- 150+ Speakers
- 14 Hours of dedicated informal networking time
- 300 organizations in attendance from 23 countries
- 76% of attendees at Director level or above.

www.bioleaders-forum.com
TOP SPEAKERS INCLUDED:

Araz Raoof, (BSc Pharmacy), PhD, MBA, Vice President, Global Functional Head CREATe (Community of Research Excellence & Advanced Technology), Janssen Research & Development, A division of Janssen Pharmaceutica NV

Dr Manuel Litchman, Vice President & Head, Oncology Business Development & Licensing, Novartis

Dr Robin Robinson, Director, Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response (ASPR), US Department of Health and Human Services (HHS)

Dr Ronald Peck, Vice President, Global Development Lead Yervoy, Bristol-Myers Squibb

Dr Devyn Smith, Chief Operating Officer, Neusentis Research Unit, Pfizer Inc

Dr Klaus Bosslet, Head, Discovery Oncology Penzberg, Pharmaceutical Research & Development (pRED), Roche Diagnostics GmbH

Dr Johan Van Hoof, Global Therapeutic Area Head, Infectious Diseases & Vaccines, Janssen Research & Development, LLC, Managing Director, Crucell

Carole A. Heilman, PhD, Director, Division of Microbiology and Infectious Diseases (DMID), NIAID, NIH

Dr Robert F. Willenbacher, Head of Cell Therapy, Janssen Research & Development, LLC

Peter F. Bross, MD, Medical Review Officer, Office of Cellular, Tissue & Gene Therapy (OCTGT), CBER, The Food & Drug Administration

Dr Rajeev Venkayya, Executive Vice President & Head of the Vaccine Business, Takeda Pharmaceuticals

Gregory MacMichael, PhD, Global Head of Advanced Therapies, Technology Research & Development, Novartis Pharma AG

Jan Thriktelle, BSc, PhD, Head Advanced Therapy Delivery, GlaxoSmithKline Medicines Research Centre

Marian W. Wentworth, Vice President, Global Vaccine Strategy & Innovation, Merck

Stewart Abbot PhD, Executive Director Integrative Research, Celgene Cellular Therapeutics

Dr Christian W. Mandl, MD, PhD, Vice President, Head of Early & Exploratory Clinical Development, Novartis Vaccines & Diagnostics, Inc

Dr Paula Salmikangas, Vice-Chair, Committee for Advanced Therapies (CAT), EMA & Senior Researcher, Finnish Medicines Agency (FIMEA)

Solomon Langermann, PhD, Senior Vice President, R&D & CSO, Amplimmune, Inc

Mitchell H. Finer, PhD, Chief Scientific Officer, bluebird bio

Roman M. Chicz, PhD, Head of Global External Research & Development, Sanofi Pasteur

Dr Mahendra Rao, Director, NIH Center for Regenerative Medicine; Laboratory Chief, Laboratory of Stem Cell Biology, NIH

Thomas Davis, MD, Chief Medical Officer & Senior Vice President, Clinical Development, Celldex Therapeutics

Donald W. Fink, Jr, PhD, Division of Cellular & Gene Therapies, Office of Cellular, Tissue & Gene Therapies (OCTGT), CBER, The Food & Drug Administration

Dr Akira Homma, President, Strategy & Policy Council, Bio-Manguinhos / Fiocruz

Dr Michel Sadelain, Director, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, NY

Dr Robert Tighe, Associate Director, ImmunoPharmacology, EMD Serono, Inc
GENERAL EVENT OVERVIEW

Phacilitate Washington celebrated its 10th Anniversary in great style, with a record attendance and overall approval rating for the event.

The Cell & Gene Therapy Forum cemented its status as the world’s premier event for the sector’s senior decision-makers. The addition of the Immunotherapy Forum – focused exclusively on active immunotherapeutic technologies – proved to be a great success given the substantial crossover between the two. Indeed, the two sessions which were shared between C&GT and Immunotherapy programmes – covering CARs and cancer vaccines respectively – were among the best received of the meeting.

The 13th Annual Phacilitate Vaccine Forum continued to drive the agenda for industry, Government and NGO leaders from the prophylactic vaccine field. Last, but not least, The Stem Cells as Discovery Research Tools event also enjoyed a successful launch, representing another welcome foray into a complementary technology area.

Summary of evaluation form feedback
(Marks are average out of 5)

The event overall: ..........4.16 (83.2%)
The Grand Hyatt Hotel: ....................................4.42
Audio-Visual: ......................................................4.52
Phacilitate customer service (pre-event): ......4.68
Phacilitate customer service (on-site): ..........4.82

ATTENDEE OVERVIEW

Organisation type:

- Pharma and biotech: 53%
- CMOs/CROs/tool and technology providers: 29%
- Govt/regulator/NGO: 8%
- Academia: 4%
- Consultant: 2%
- Press: 2%
- Other: 2%

Seniority:

- CXO/President/Board member/Chairman: 23%
- Managing Director/VP/SVP/VP: 24%
- Exec. Director/Senior Director/Partner: 29%
- Senior Manager/Manager: 21%
- Other: 3%

External stakeholders included:

Aeras • Alliance for Regenerative Medicine • Bio-Manguinhos / Fiocruz • Biotechnology Industry Organization (BIO) • Boston Children’s Hospital • Butantan Institute • California Institute for Regenerative Medicine (CIRM) • CASMI/University of Oxford • Centre for Commercialization of Regenerative Medicine (CCRM) • Emory University • European Medicines Agency (EMA) • Finnish Medicines Agency (FIMEA) • Foundation Fighting Blindness • Fraunhofer IME • Fred Hutchinson Cancer Research Center • Georgetown University • Georgia Institute of Technology • Global Biological Standards Institute • Harvard Stem Cell Institute • Health Sciences Authority, Singapore • Human Stem Cells Institute • International Stem Cell Society (STEMSO) • Japan Science and Technology Agency • Japanese Pharmaceuticals and Medical Devices Agency (PMDA) • Johns Hopkins University School of Medicine • Malaria Vaccine Initiative • McGill University • MD Anderson Cancer Center • Memorial Sloan Kettering Cancer Center, NY • MSD Wellcome Trust Hilleman Laboratories PVT. LTD. • National Disease Research Interchange • NIH • NIST • NY Stem Cell Foundation • Ottawa Hospital Research Institute • PACT • PAHO/WHO • PATH • Royal College of Surgeons in Ireland • Southern Illinois University School of Medicine • The New York Stem Cell Foundation • The Stop ALD Foundation • Tokyo Medical University • University of Maryland School of Medicine • University Of Pennsylvania • University of Sussex • University of Tampere / BioMediTech • University of Texas Health Science Center at Houston • US Department of Health and Human Services (HHS) • US FDA • Yale Cancer Center

The event featured a number of other ‘firsts’ and records for Phacilitate:

• The launch of the annual Bioleaders Power 10 award at our Gala Dinner (attended by around 200 attendees). The inaugural award was presented to Dr Anthony Fauci, Director of NIAID, NIH. His award was accepted on his behalf by Dr Carole Heilman, Director of DMID.

• Overall, Phacilitate Washington attracted well over 500 attendees to Washington, DC.

• 60 sponsors and exhibitors supported the event

Pharma and biotech companies at Phacilitate Washington included:

Adaptimmune • Advantagene, Inc. • Amplymune • apceth GmbH & Co. KG • Areta International SrI • Argos Therapeutics • Artificial Cell Technologies • ASKLEPIDS BioPharmaceuticals, Inc. • Astellas Pharma • Asterias Biotherapeutics, Inc. • Athereos, Inc • Bavarian Nordic • Baxter Healthcare Corporation • Bellcum Pharmaceuticals • Benitec Biopharma • BioGen Idec • Biovest International • Bluebird bio • Bristol-Myers Squibb • Celgene Cellular Therapeutics • Celladon Corporation • Celdiex Therapeutics • Celltech • Cellular Dynamics International (CDI) • Cellular Technology Ltd. (C.T.L.) • Compugen • Crucell • CureVac GmbH • Cytoprofati Tissue Engineering • CytoMedix, Inc. • Daiichi Sankyo • DBV Technologies • EMD Serona • Emergent Biosolutions • Fibrocell Science, Inc. • Gamida Cell Ltd • Genable Technologies Limited • Genentech • Genethon • GenVec, Inc. • GeoVax • GlaxoSmithKline • GlaxoSmithKline Biologicals • GRICEL SA • Hemostemix • Immatics biotechnologies • Immune Design • Immunovaccine • ISA Therapeutics BV • Janssen Pharmaceutical companies of Johnson & Johnson • Jennexex Biotherapeutics • Juno Therapeutics, Inc. • Kiads Pharma • Lentigen Corporation • Lion Biotechnologies, Inc • MatrixV R&D Corp • Memcine • Merck & Co, Inc. • Mesoblast • MolMed S.p.A. • NanoBio Corporation • Nanotherapeutics, Inc. • NeoStem, Inc. • NexImmune, Inc. • Northwest Biotherapeutics • Novartis Pharma • Novartis Vaccines and Diagnostics • Novavax • Onco Therapics • OncoThyreon • Opexa Therapeutics, Inc. • ORCA Therapeutics • Organogenesis Inc • Organex Inc • PaxVax • PBS Biotech, Inc. • PCI Biotech AS • Pfizer • Pluristem Therapeutics Inc • Protectus BioSciences, Inc • PROMERA Biosciences SA/NV • Protein Sciences • Prothermune • ReGenX Biosciences • Ribogical GmbH • Roche Diagnostics GmbH • Sangamo BioSciences • Sanofi • Sanofi Pasteur • Selecta Biosciences • Shire Pharmaceuticals • Smith & Nephew Biotherapeutics • Spark Therapeutics • Stallergenes • SutroVax Inc • Takeda Pharmaceuticals • TissueGene, Inc • Tocagen • TxCell SA • Vaccingen, Inc • Vedanta Pharmaceuticals • Vital Therapies, Inc.

Sponsors & exhibitors included:

Platinum sponsors

Fisher BioServices • Thermo Scientific

Gold sponsors

Biovest International • PCT • Valneva

Silver sponsors

Angocrine • Moxipharma • OxfordBiomedica • CATAPULT • ApoPharma • medicago • Biologics Life Sciences • 63 Healthcare Life Sciences • NovoNorthwest Biopharmaceuticals

Technology Spotlight Sponsor

InterMune

Bronze sponsors

Invotech • Lonza • TERUMOBCT • MABIS • Miltenyi Biotec

Literature Sponsor

Cell Therapeautics • Catalent • Janssen Pharmaceutical companies of Johnson & Johnson

Associate sponsor

NDA • CANS

Exhibitors

AERAS • BCA • CellGenix • CellTherapy Group • IFT • Immunocore • PARAGON • SAWT • TAP Biosystems • VaxNetwork • Valneva

Media Partners

ARCS • Alliance • ISBiology • BD • DNAvacciino • Human Vaccines & Immunotherapeutics • Fresenius Kabi
SPONSORS AND EXHIBITORS ALREADY BOOKED FOR 2015 INCLUDE:

Have your say on these ideas, or confirm your involvement – contact Phacilitate today!

For information on sponsorship and/or exhibiting:
Michael Adeniyi, Business Development Director
t: +44 (0) 7384 7951
e: michael@phacilitate.co.uk

For delegate enquiries:
Kim Evans, Programme Manager
t: +44 (0) 7384 7993
e: kim@phacilitate.co.uk

For input regarding content and format for the agenda, and event as a whole:
David McCall, Portfolio Director
t: +44 (0)20 7384 8050
e: david@phacilitate.co.uk

For marketing enquiries:
Carina Hunter, Marketing Manager
e: carina.hunter@clarionevents.com
t: +44 (0)20 7384 7897

WHAT’S HAPPENING IN 2015?

- Expanded Cell & Gene Therapy Forum and Immunotherapy Forum agendas, including dedicated 3-days streams focusing on manufacturing business models and technologies, R&D/clinical development, logistics, regulatory affairs and more
- New app-based pre-event online networking service
- Largest ever speaker panel – expect well over 150 bioleaders
- Annual Gala Awards Dinner
- Redesigned and expanded exhibition area
- Novel formats that we are looking to build into the conference agenda include:
  - Interactive ‘Meet the Professor’ sessions – academic opinion leaders in open Q&A
  - Working Lunch discussions for small groups
  - ‘Tech room’ demonstrations
  - White paper/clinical review data sessions
  - 1-on-1 regulatory ‘drop in clinics’
  - Speed networking sessions
  - ‘Behind Closed Doors’ Advisory Board-led summit meetings, complete with an exclusive post-event report on conclusions and strategic action points for participants.

SAV E  THE  D ATE
THE GRAND HYATT WASHINGTON, DC
JANUARY 26TH-28TH

www.bioleaders-forum.com